Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMAS: Semaglutide Anti-Atherosclerotic Mechanisms of Action Study
NCT05147896Unknown
- Sponsor
- University Medical Centre Ljubljana
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of semaglutide in type 2 diabetes mellitus (T2DM) and atherosclerosis (2 arms), sponsored by University Medical Centre Ljubljana. Primary endpoints: Change in morphological arterial wall characteristics at 1 year, Change in functional arterial wall characteristics at 1 year and 1 more. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerosis
Beyond the preview
Go deeper on NCT05147896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147896.